Abstracts tagged "Activity score"

Abstract Number: 610 • 2012 ACR/ARHP Annual Meeting
B Lymphocyte Stimulator Levels Are Higher in Caucasian SLE Patients Earlier in Disease Course and Predict Damage Accumulation
Eoghan M. McCarthy¹, Ruth Lee¹, Joan Ni Gabhann², Siobhan Smith², Michele Doran³, Gaye Cunnane³, Donough G. Howard¹, Paul G. O'Connell⁴, Grainne M. Kearns⁵ and Caroline Jefferies², ¹Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ²Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland, ³Dept of Rheumatology, St. James Hospital, Dublin, Ireland, ⁴Department of Rheumatology, Beaumont Hospital, Dublin 9, Ireland, ⁵Rheumatology Department, Beaumont Hospital, Dublin, Ireland

Background/Purpose: B Lymphocyte Stimulator(BLyS) plays an important role in the pathogenesis of Systemic Lupus Erythematosus(SLE). Whilst trials of anti BLyS-targeted therapy have shown promise, the optimal…
Abstract Number: 2382 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen is an Accurate Marker of Disease Activity in Patients with Polymyalgia Rheumatica
E.M. McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland

Background/Purpose: Accurate determination of disease activity in polymyalgia rheumatica(PMR) is challenging due to the subjective nature of symptoms and concurrent musculoskeletal complaints in an elderly…
Abstract Number: 563 • 2012 ACR/ARHP Annual Meeting
In Ankylosing Spondylitis, a Decrease in MRI Spinal Inflammation Predicts Improvement in Spinal Mobility Independently of Patient Reported Symptomatic Improvement
Pedro Machado¹, Robert Landewé², Jürgen Braun³, Xenofon Baraliakos⁴, Kay-Geert A. Hermann⁵, Benjamin Hsu⁶, Daniel Baker⁷ and Désirée van der Heijde¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Clinical Immunology & Rheumatology, Academic Medical Center, University of Amsterdam and Atrium Medical Center, Heerlen, Netherlands, ³PsAID taskforce, EULAR, Zurich, Switzerland, ⁴Rheumatology, Rheumazentrum Ruhrgebiet, Herne, Germany, ⁵Radiology, Charité Universitätsmedizin Berlin, Campus Mitte, Berlin, Germany, ⁶Janssen Research & Development, LLC., Spring House, PA, ⁷Research and Development, Centocor Inc., Malvern/Philadelphia, PA
Background/Purpose: It has been previously shown that spinal mobility in ankylosing spondylitis (AS) is associated with the level of inflammation of the spine. However an…
Abstract Number: 2348 • 2012 ACR/ARHP Annual Meeting
Plasma Fibrinogen Better Identifies Persistent Disease Activity in Polymyalgia Rheumatica Than Either ESR or CRP
EM McCarthy¹, Paul A. MacMullan¹, S. Al-Mudhaffer¹, Anne M. Madigan¹, S. Donnelly¹, C. J. McCarthy¹, Dermot Kenny², Eamonn Molloy³ and G M. McCarthy¹, ¹Rheumatology, Mater Misericordiae University Hospital, Dublin 7, Ireland, ²Molecular and Cellular Therapeutics, RCSI, Dublin 2, Ireland, ³Rheumatology, Dublin Academic Medical Centre, St. Vincent's University Hospital, Dublin, Ireland
Background/Purpose: In PMR careful tailoring of the glucocorticoid dosage to the patients needs is crucial to avoid the risk of treatment-related adverse effects and the…
Abstract Number: 546 • 2012 ACR/ARHP Annual Meeting
The Immunogenicity to the First Anti-TNF Therapy Determines the Outcome of Switching to a Second Anti-TNF in Spondyloarthritis Patients
Chamaida Plasencia¹, Dora Pascual-Salcedo², Sara Garcia-Carazo³, Gema Bonilla⁴, Leticia Lojo⁵, Laura Nuño⁶, Alejandro Villalba⁷, Diana Peiteado⁷, Concepcion Castillo-Gallego⁷, Florencia Arribas², Daniel Nagore⁸, E. Martin-Mola⁹ and Alejandro Balsa⁴, ¹Rheumatology, Hospital La Paz-IdiPaz, Madrid, Spain, ²Immunology, Hospital La Paz. IdiPaz, Madrid, Spain, ³La PAZ University Hospital, RHEUMATOLOGY UNIT, Spain, Spain, ⁴Rheumatology, Hospital La Paz, Madrid, Spain, ⁵Rheumatology, Hospital Universitario La Paz, Spain, Spain, ⁶Hospital La Paz-IdiPaz, Madrid, Spain, ⁷Rheumatology, Hospital La Paz - IdiPaz, Madrid, Spain, ⁸Proteomika S.L., ⁹Servicio de Reumatología, Hospital Universitario La Paz, Madrid, Spain
Background/Purpose: Spondyloarthropathies (SpAs) encompass a heterogeneous group of diseases that primarily affect the axial skeleton and entheses. Although anti-TNF drugs have proven to be effective…
Abstract Number: 2121 • 2012 ACR/ARHP Annual Meeting
A Multi-Biomarker Disease Activity (VECTRA™ DA Algorithm) Score Reflects Clinical Disease Activity and Structural Changes in Rheumatoid Arthritis Patients Treated with Tocilizumab
Yoshiya Tanaka¹, Kentaro Hanami², Hisashi Tasaka¹, Shunsuke Fukuyo¹, Douglas J. Haney³, Nadine Defranoux³, Rebecca Bolce³, Guy Cavet³, David Chernoff³, Kunihiro Yamaoka¹, Kazuyoshi Saito¹ and Shintaro Hirata¹, ¹The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ²The First Department of Internal Medicinei, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan, ³Crescendo Bioscience Inc., South San Francisco, CA
Background/Purpose: The multi-biomarker disease activity (MBDA) score assessed with 0.2 mL serum has been reported as a novel composite disease activity index for patients with…
Abstract Number: 421 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Factor, Not Antibodies to Citrullinated Proteins, Are Associated with High Disease Activity
Josef S. Smolen¹, Farideh Alasti² and Daniel Aletaha³, ¹Medical University of Vienna and Hietzing Hospital, Vienna, Austria, ²Department of Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria
Background/Purpose: Autoantibodies in general, and rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) in particular, are a hallmark of RA. After their characterization, ACPA have…
Abstract Number: 2008 • 2012 ACR/ARHP Annual Meeting
Initial Evaluation of a Localized Scleroderma (LS) Clinical Activity Measure
Suzanne C. Li¹, Kathryn S. Torok², Christina Kelsey³, Mara L Becker⁴, Fatma Dedeoglu⁵, Robert C. Fuhlbrigge⁶, Gloria C. Higgins⁷, Sandy D. Hong⁸, Maria F. Ibarra⁹, Ronald Laxer¹⁰, Thomas G. Mason II¹¹, Marilynn G. Punaro¹², Elena Pope¹³, C. Egla Rabinovich¹⁴ and Katie G. Stewart¹², ¹Pediatrics, Joseph M Sanzari Children's Hospital, Hackensack University Medical Center, Hackensack, NJ, ²Pediatric Rheumatology, Scleroderma Center of Pittsburgh, Children's Hospital of Pittsburgh of UPMC, Pittsburgh, PA, ³Pediatric Rheumatology, Univ of Pittsburgh Med Ctr, Pittsburgh, PA, ⁴Clinical Pharmacology and Rheumatology, Children's Mercy Hospital, Kansas City, MO, ⁵Division of Immunology, Boston Children's Hospital, Boston, MA, ⁶Pediatric Rheumatology, Childrens Hospital, Boston, MA, ⁷Pediatric Rheumatology Ohio State University, Nationwide Childrens Hosp, Columbus, OH, ⁸Pediatrics-Rheumatology, U of Iowa Children's Hosp, Iowa City, IA, ⁹Pediatric Rheumatolgy, Children's Mercy Hospital, Kansas City, MO, ¹⁰Rheumatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹¹Rheumatology, Mayo Clinic Rochester, Rochester, MN, ¹²Pediatric Rheumatology, Texas Scottish Rite Hospital, Dallas, TX, ¹³Dermatology, The Hospital for Sick Children, Toronto, ON, Canada, ¹⁴Pediatric Rheumatology, Duke University Medical Center, Durham, NC
Background/Purpose: LS commonly causes severe morbidity for the growing child. Optimal therapy is not known and the lack of an agreed-upon standard for assessing disease…
Abstract Number: 393 • 2012 ACR/ARHP Annual Meeting
Defining Criteria for Rheumatoid Arthritis Patient-Derived Disease Activity Score That Corrresponds to Disease Activity Score 28 and Clnical Disease Activity Index Based Statuses and Response Criteria
Alexander MH Leung¹, Daniel Farewell², Chak S. Lau³ and Ernest Choy⁴, ¹Department of Rheumatology, Institute of Infection and Immunity, Cardiff University School of Medicine, Cardiff, United Kingdom, ²Institute of Primary Care and Public Health, Cardiff, ENGLAND, United Kingdom, ³Univ Dept of Medicine, Queen Mary Hospital, Hong Kong, Hong Kong, ⁴Section of Rheumatology, Cardiff University School of Medicine, Cardiff, United Kingdom
Background/Purpose: Patient-based disease activity score (PDAS1 [with ESR] & PDAS2 [without ESR]) in rheumatoid arthritis (RA) are validated patient reported outcome measures of disease activity.…
Abstract Number: 1570 • 2012 ACR/ARHP Annual Meeting
Discrepancies Between Disease Activity and Disease Burden
Margot J.M. Walter¹, Adriaan van 't Spijker², Annelieke Pasma³, Johanna M.W. Hazes⁴ and Jolanda J. Luime⁴, ¹Rheumatology, Erasmus MC - University Medical Center, Rotterdam, Netherlands, ²Psychiatry, section Medical Psychology and Psychotherapy, Erasmus MC University Medical Center, Rotterdam, Netherlands, ³Rheumatology, Erasmus MC University Medical Center, Rotterdam, Netherlands, ⁴Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands

Background/Purpose: In a longitudinal study aiming to use patient self-reported disease activity measured by three domains: functional ability (HAQ), disease activity (RADAI) and fatigue (VAS)…
Abstract Number: 402 • 2012 ACR/ARHP Annual Meeting
Discordant Inflammatory Markers in Veterans with Rheumatoid Arthritis: Baseline Characteristics and Relationship with Disease Activity
Rebecca Belsom¹, Archana Jain¹, Jeffrey R. Curtis², Shuo Yang³, Ted R. Mikuls⁴, Lang Chen⁵ and Angelo L. Gaffo⁶, ¹Rheumatology, University of Alabama, Birmingham, AL, ²Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ³Clinical Immunology/Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁴Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ⁵Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁶Medicine, Birmingham VA Medical Center and University of Alabama at Birmingham, Birmingham, AL
Background/Purpose: Discrepancies between erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) elevations with clinical disease activity frequently occur in rheumatoid arthritis (RA) patients and may…

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].